Notícias

Rinvoq, Comirnaty and Opzelura have all received their own EC approvals this week.

Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here’s what to look for.

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

But is that performance sustainable?

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

AbbVie still looks like a compelling buy at its all-time high.

AbbVie stock has delivered strong returns over the past five years, yet the current valuation picture is split, with the intrinsic value estimate pointing to upside while market multiples suggest the shares screen rich. AbbVie has returned 172.0% over five years, which puts extra focus on whether the current price still offers an attractive entry for new capital. Recent European approvals for RINVOQ and Allergan Aesthetics' Boey can support expectations for future cash flows, while mixed...

AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago, investors were restless. The two drugs carrying the company were doing fine, but everyone already knew that, and the market wanted a new reason to invest. Goldman Sachs went ...

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen AbbVie's immunology pipeline.

AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.

DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the next decade.

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

S&P 500 companies' second-quarter earnings growth reached 70%, driven by the information technology

A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.

The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.

Both have very promising futures.

Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.

Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its overall survival primary endpoint, raising fresh questions about the drug's long term commercial potential. See our latest analysis for AbbVie. Against this backdrop, AbbVie’s share price has had a strong run, with a 30-day share price return of 10.42% and a 90-day share price return of 30.52%. Its 1-year total shareholder return of 40.53% highlights momentum...

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

Just over a month since its initial public offering, SpaceX has delivered one of the weakest post-debut performances of any major U.S. listing since the end of the 2008-2009 financial crisis. A Barron’s analysis found that the stock performed worse than 90% of other U.S. IPOs with market capitalizations of $1 billion or more since July, 2009. Over the first 27 trading days, SpaceX was down 23% from its first day closing price of $161.